IL-13 receptor-α2: a novel target for cancer therapy-Reference-Cited by-同舟云学术

IL-13 receptor-α2: a novel target for cancer therapy

Published:2009-05 Issue:3 Volume:1 Page:321-327
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Joshi Bharat H¹,Puri Raj K²

Affiliation:

1. Tumor Vaccines & Biotechnology Branch, Division of Cellular & Gene Therapies, Center for Biologics Evaluation & Research, US FDA.

2. Tumor Vaccines & Biotechnology Branch, Division of Cellular & Gene Therapies, Center for Biologics Evaluation & Research, US Food & Drug Administration, NIH Building 29B, Room 2NN20, Bethesda, MD 20892, USA.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt.09.8

Reference78 articles.

1. Receptor for Interleukin (IL) 13 Does Not Interact with IL4 but Receptor for IL4 Interacts with IL13 on Human Glioma Cells

2. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering the IL‐4/IL‐13 axis for targeted immune modulation;Immunological Reviews;2023-06-07

2. Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide;Cancers;2023-05-16

3. IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma;Pharmaceutics;2022-04-24

4. IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer;Diagnostics;2021-06-23

5. IL-13Rα2 gene expression is a biomarker of adverse outcome in patients with adrenocortical carcinoma;PLOS ONE;2021-02-16